Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 381

1.

Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1.

Ustun C, Kim S, Chen M, Beitinjaneh AM, Brown VI, Dahi PB, Daly A, Diaz MA, Freytes CO, Ganguly S, Hashmi S, Hildebrandt GC, Lazarus HM, Nishihori T, Olsson RF, Page KM, Papanicolaou G, Saad A, Seo S, William BM, Wingard JR, Wirk B, Yared JA, Perales MA, Auletta JJ, Komanduri KV, Lindemans CA, Riches ML.

Blood Adv. 2019 Sep 10;3(17):2525-2536. doi: 10.1182/bloodadvances.2019000226.

2.

Corrigendum to "Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features".

Khan AM, Muzaffar J, Murthy H, Wingard JR, Moreb JS.

Case Rep Hematol. 2019 Aug 4;2019:1548610. doi: 10.1155/2019/1548610. eCollection 2019.

3.

A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.

Drusbosky LM, Singh NK, Hawkins KE, Salan C, Turcotte M, Wise EA, Meacham A, Vijay V, Anderson GG, Kim CC, Radhakrishnan S, Ullal Y, Talawdekar A, Sikora H, Nair P, Khanna-Gupta A, Abbasi T, Vali S, Guha S, Farhadfar N, Murthy HS, Horn BN, Leather HL, Castillo P, Tucker C, Cline C, Pettiford L, Lamba JK, Moreb JS, Brown RA, Norkin M, Hiemenz JW, Hsu JW, Slayton WB, Wingard JR, Cogle CR.

Blood Adv. 2019 Jun 25;3(12):1837-1847. doi: 10.1182/bloodadvances.2018028316.

4.

Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors.

Majhail NS, Murphy E, Laud P, Preussler JM, Denzen EM, Abetti B, Adams A, Besser R, Burns LJ, Cerny J, Drexler R, Hahn T, Idossa L, Jahagirdar B, Kamani N, Loren A, Mattila D, McGuirk J, Moore H, Reynolds J, Saber W, Salazar L, Schatz B, Stiff P, Wingard JR, Syrjala KL, Baker KS.

Haematologica. 2019 May;104(5):1084-1092. doi: 10.3324/haematol.2018.203919. Epub 2018 Dec 4.

5.

CD34+ chimerism analysis for minimal residual disease monitoring after allogeneic hematopoietic cell transplantation.

Unnikrishnan A, Meacham AM, Goldstein SS, Ta M, Leather HL, Cogle CR, Castillo P, Wingard JR, Norkin M.

Leuk Res. 2018 Nov;74:110-112. doi: 10.1016/j.leukres.2018.10.007. Epub 2018 Oct 18. No abstract available.

PMID:
30401521
6.

Tailoring a Survivorship Care Plan: Patient and Provider Preferences for Recipients of Hematopoietic Cell Transplantation.

Denzen EM, Preussler JM, Murphy EA, Baker KS, Burns LJ, Foster J, Idossa L, Moore HK, Payton TJ, Haven D, Jahagirdar B, Kamani N, Rizzo JD, Salazar L, Schatz BA, Syrjala KL, Wingard JR, Majhail NS.

Biol Blood Marrow Transplant. 2019 Mar;25(3):562-569. doi: 10.1016/j.bbmt.2018.10.005. Epub 2018 Oct 10.

PMID:
30315940
7.

How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers.

Sundermann AJ, Clancy CJ, Pasculle AW, Liu G, Cumbie RB, Driscoll E, Ayres A, Donahue L, Pergam SA, Abbo L, Andes DR, Chandrasekar P, Galdys AL, Hanson KE, Marr KA, Mayer J, Mehta S, Morris MI, Perfect J, Revankar SG, Smith B, Swaminathan S, Thompson GR, Varghese M, Vazquez J, Whimbey E, Wingard JR, Nguyen MH.

Clin Infect Dis. 2019 Feb 15;68(5):850-853. doi: 10.1093/cid/ciy669.

PMID:
30299481
8.

Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation.

Norkin M, Shaw BE, Brazauskas R, Tecca HR, Leather HL, Gea-Banacloche J, T Kamble R, DeFilipp Z, Jacobsohn DA, Ringden O, Inamoto Y, A Kasow K, Buchbinder D, Shaw P, Hematti P, Schears R, Badawy SM, Lazarus HM, Bhatt N, Horn B, Chhabra S, M Page K, Hamilton B, Hildebrandt GC, Yared JA, Agrawal V, M Beitinjaneh A, Majhail N, Kindwall-Keller T, Olsson RF, Schoemans H, Gale RP, Ganguly S, A Ahmed I, Schouten HC, L Liesveld J, Khera N, Steinberg A, Shah AJ, Solh M, Marks DI, Rybka W, Aljurf M, Dietz AC, Gergis U, George B, Seo S, Flowers MED, Battiwalla M, Savani BN, Riches ML, Wingard JR.

Biol Blood Marrow Transplant. 2019 Feb;25(2):362-368. doi: 10.1016/j.bbmt.2018.09.031. Epub 2018 Oct 2.

PMID:
30287390
9.

Vaccinating donors for hematopoietic cell transplantation: A systematic review and future perspectives.

Muhsen IN, Aljurf M, Wingard JR, Poland GA, Komanduri KV, Whitaker JA, Hashmi SK.

Vaccine. 2018 Oct 1;36(41):6043-6052. doi: 10.1016/j.vaccine.2018.08.044. Epub 2018 Sep 6. Review.

PMID:
30195488
10.

PCR-Based Approach Targeting Mucorales-Specific Gene Family for Diagnosis of Mucormycosis.

Baldin C, Soliman SSM, Jeon HH, Alkhazraji S, Gebremariam T, Gu Y, Bruno VM, Cornely OA, Leather HL, Sugrue MW, Wingard JR, Stevens DA, Edwards JE Jr, Ibrahim AS.

J Clin Microbiol. 2018 Sep 25;56(10). pii: e00746-18. doi: 10.1128/JCM.00746-18. Print 2018 Oct.

11.

The microbiome: more than a gut reaction.

Wingard JR.

Blood. 2018 Jun 28;131(26):2874-2875. doi: 10.1182/blood-2018-05-847509. No abstract available.

12.

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM.

Lancet Haematol. 2018 Nov;5(11):e563-e598. doi: 10.1016/S2352-3026(18)30051-6. Epub 2018 Jun 18. Review. Erratum in: Lancet Haematol. 2019 Mar;6(3):e121.

13.

Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features.

Khan AM, Muzaffar J, Murthy H, Wingard JR, Moreb JS.

Case Rep Hematol. 2018 Feb 12;2018:9052314. doi: 10.1155/2018/9052314. eCollection 2018. Erratum in: Case Rep Hematol. 2019 Aug 4;2019:1548610.

14.

Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation.

Davies JK, Brennan LL, Wingard JR, Cogle CR, Kapoor N, Shah AJ, Dey BR, Spitzer TR, de Lima M, Cooper LJ, Thall PF, Champlin RE, Nadler LM, Guinan EC.

Clin Cancer Res. 2018 Sep 1;24(17):4098-4109. doi: 10.1158/1078-0432.CCR-18-0449. Epub 2018 May 16.

15.

ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors.

Hashmi SK, Lee SJ, Savani BN, Burns L, Wingard JR, Perales MA, Palmer J, Chow E, Meyer E, Marks D, Mohty M, Inamoto Y, Rodriguez C, Nagler A, Sauter C, Komanduri KV, Pidala J, Hamadani M, Johnston L, Shah N, Shaughnessy P, Hamilton BK, Majhail N, Kharfan-Dabaja MA, Schriber J, DeFilipp Z, Tarlock KG, Fanning S, Curtin P, Rizzo JD, Carpenter PA.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1119-1124. doi: 10.1016/j.bbmt.2018.03.023. Epub 2018 Mar 30.

16.

Severity, course, and predictors of sleep disruption following hematopoietic cell transplantation: a secondary data analysis from the BMT CTN 0902 trial.

Jim HSL, Sutton S, Majhail NS, Wood WA, Jacobsen PB, Wingard JR, Wu J, Knight JM, Syrjala KL, Lee SJ.

Bone Marrow Transplant. 2018 Aug;53(8):1038-1043. doi: 10.1038/s41409-018-0138-0. Epub 2018 Mar 7.

17.

The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future.

Andermann TM, Peled JU, Ho C, Reddy P, Riches M, Storb R, Teshima T, van den Brink MRM, Alousi A, Balderman S, Chiusolo P, Clark WB, Holler E, Howard A, Kean LS, Koh AY, McCarthy PL, McCarty JM, Mohty M, Nakamura R, Rezvani K, Segal BH, Shaw BE, Shpall EJ, Sung AD, Weber D, Whangbo J, Wingard JR, Wood WA, Perales MA, Jenq RR, Bhatt AS; Blood and Marrow Transplant Clinical Trials Network.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1322-1340. doi: 10.1016/j.bbmt.2018.02.009. Epub 2018 Feb 19. Review. No abstract available.

18.

Applying host disease status biomarkers to therapeutic response monitoring in invasive aspergillosis patients.

Zhao Y, Nagasaki Y, Paderu P, Sugrue MW, Leather HL, Wingard JR, Perlin DS.

Med Mycol. 2019 Jan 1;57(1):38-44. doi: 10.1093/mmy/myx164.

PMID:
29370415
19.

Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.

Norkin M, Katragadda L, Zou F, Xiong S, Chang M, Dai Y, Hsu JW, Moreb JS, Leather H, Murthy HS, Farhadfar N, Li Y, Hromas R, Brown RA, Cogle CR, Wingard JR.

Blood Cancer J. 2017 Nov 27;7(12):634. doi: 10.1038/s41408-017-0007-x.

20.

Recent advances in hematopoietic stem cell transplantation.

Norkin M, Wingard JR.

F1000Res. 2017 Jun 12;6:870. doi: 10.12688/f1000research.11233.1. eCollection 2017. Review.

21.

Complete resolution of severe ulcerative colitis after haploidentical hematopoietic stem cell transplantation followed by post-transplant high-dose cyclophosphamide.

Unnikrishnan A, Glover SC, Norkina O, Wingard JR, Norkin M.

Bone Marrow Transplant. 2017 Aug;52(8):1204-1205. doi: 10.1038/bmt.2017.94. Epub 2017 Jun 5. No abstract available.

PMID:
28581471
22.

Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity.

Moguillansky NI, Fakih HAM, Wingard JR.

Respir Med Case Rep. 2017 May 10;21:154-157. doi: 10.1016/j.rmcr.2017.05.003. eCollection 2017.

23.

Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.

Moreb JS, Byrne M, Shugarman I, Zou F, Xiong S, May WS, Norkin M, Hiemenz J, Brown R, Cogle C, Wingard JR, Hsu JW.

J Clin Apher. 2018 Feb;33(1):29-37. doi: 10.1002/jca.21556. Epub 2017 May 29.

PMID:
28556233
24.

Guarded promise for adenovirus therapy.

Wingard JR.

Blood. 2017 Apr 6;129(14):1899-1900. doi: 10.1182/blood-2017-02-767582. No abstract available.

25.

Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy.

Seay HR, Putnam AL, Cserny J, Posgai AL, Rosenau EH, Wingard JR, Girard KF, Kraus M, Lares AP, Brown HL, Brown KS, Balavage KT, Peters LD, Bushdorf AN, Atkinson MA, Bluestone JA, Haller MJ, Brusko TM.

Mol Ther Methods Clin Dev. 2016 Dec 24;4:178-191. doi: 10.1016/j.omtm.2016.12.003. eCollection 2017 Mar 17.

26.

Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study.

Maziarz RT, Brazauskas R, Chen M, McLeod AA, Martino R, Wingard JR, Aljurf M, Battiwalla M, Dvorak CC, Geroge B, Guinan EC, Hale GA, Lazarus HM, Lee JW, Liesveld JL, Ramanathan M, Reddy V, Savani BN, Smith FO, Strasfeld L, Taplitz RA, Ustun C, Boeckh MJ, Gea-Banacloche J, Lindemans CA, Auletta JJ, Riches ML.

Bone Marrow Transplant. 2017 Feb;52(2):270-278. doi: 10.1038/bmt.2016.259. Epub 2016 Dec 19.

27.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.

Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agúndez J, Wingard JR, McLeod HL, Klein TE, Cross SJ, Caudle KE, Walsh TJ.

Clin Pharmacol Ther. 2017 Jul;102(1):45-51. doi: 10.1002/cpt.583. Epub 2017 Apr 18. Erratum in: Clin Pharmacol Ther. 2018 Feb;103(2):349.

28.

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Gea-Banacloche J, Komanduri KV, Carpenter P, Paczesny S, Sarantopoulos S, Young JA, El Kassar N, Le RQ, Schultz KR, Griffith LM, Savani BN, Wingard JR.

Biol Blood Marrow Transplant. 2017 Jun;23(6):870-881. doi: 10.1016/j.bbmt.2016.10.001. Epub 2016 Oct 14. Review.

29.

Pretransplantation Exercise and Hematopoietic Cell Transplantation Survival: A Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902).

Wingard JR, Wood WA, Martens M, Le-Rademacher J, Logan B, Knight JM, Jacobsen PB, Jim H, Majhail NS, Syrjala K, Rizzo JD, Lee SJ.

Biol Blood Marrow Transplant. 2017 Jan;23(1):161-164. doi: 10.1016/j.bbmt.2016.10.007. Epub 2016 Oct 11.

30.

Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial.

Knight JM, Syrjala KL, Majhail NS, Martens M, Le-Rademacher J, Logan BR, Lee SJ, Jacobsen PB, Wood WA, Jim HSL, Wingard JR, Horowitz MM, Abidi MH, Fei M, Rawls L, Rizzo JD.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2256-2263. doi: 10.1016/j.bbmt.2016.08.016. Epub 2016 Aug 23.

31.

A sniff to chase ill humors away.

Wingard JR.

Blood. 2016 Aug 18;128(7):889-90. doi: 10.1182/blood-2016-06-723932. No abstract available.

32.

Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE.

Clin Infect Dis. 2016 Aug 15;63(4):433-42. doi: 10.1093/cid/ciw444.

33.

Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee.

Palmer J, McCune JS, Perales MA, Marks D, Bubalo J, Mohty M, Wingard JR, Paci A, Hassan M, Bredeson C, Pidala J, Shah N, Shaughnessy P, Majhail N, Schriber J, Savani BN, Carpenter PA.

Biol Blood Marrow Transplant. 2016 Nov;22(11):1915-1925. doi: 10.1016/j.bbmt.2016.07.013. Epub 2016 Jul 29. Review.

34.

A Prospective Biopsychosocial Investigation Into Head and Neck Cancer Caregiving.

Nightingale CL, Pereira DB, Curbow BA, Wingard JR, Carnaby GD.

Biol Res Nurs. 2017 Jan;19(1):87-96. doi: 10.1177/1099800416660760. Epub 2016 Jul 28.

35.

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE.

Clin Infect Dis. 2016 Aug 15;63(4):e1-e60. doi: 10.1093/cid/ciw326. Epub 2016 Jun 29.

36.

Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation.

Ballen K, Woo Ahn K, Chen M, Abdel-Azim H, Ahmed I, Aljurf M, Antin J, Bhatt AS, Boeckh M, Chen G, Dandoy C, George B, Laughlin MJ, Lazarus HM, MacMillan ML, Margolis DA, Marks DI, Norkin M, Rosenthal J, Saad A, Savani B, Schouten HC, Storek J, Szabolcs P, Ustun C, Verneris MR, Waller EK, Weisdorf DJ, Williams KM, Wingard JR, Wirk B, Wolfs T, Young JH, Auletta J, Komanduri KV, Lindemans C, Riches ML.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1636-1645. doi: 10.1016/j.bbmt.2016.06.012. Epub 2016 Jun 22.

37.

Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.

Katragadda L, McCullough LM, Dai Y, Hsu J, Byrne M, Hiemenz J, May S, Cogle CR, Norkin M, Brown RA, Wingard JR, Chang M, Moreb JS.

Clin Transplant. 2016 Aug;30(8):894-900. doi: 10.1111/ctr.12762. Epub 2016 Jun 29.

PMID:
27219740
38.

A new model to predict remission status in AML patients based on day 14 bone marrow biopsy.

Norkin M, Chang M, An Q, Leather H, Katragadda L, Li Y, Moreb JS, May WS, Brown RA, Hsu JW, Hiemenz JW, Wingard JR, Cogle CR.

Leuk Res. 2016 Jul;46:69-73. doi: 10.1016/j.leukres.2016.04.013. Epub 2016 Apr 20.

PMID:
27132034
39.

Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial.

Hope WW, Walsh TJ, Goodwin J, Peloquin CA, Howard A, Kurtzberg J, Mendizabal A, Confer DL, Bulitta J, Baden LR, Neely MN, Wingard JR; Blood and Marrow Transplant Clinical Trials Network.

J Antimicrob Chemother. 2016 Aug;71(8):2234-40. doi: 10.1093/jac/dkw127. Epub 2016 Apr 27.

40.

Association of mannose-binding lectin levels and invasive fungal disease in hematologic malignancy patients receiving myelosuppressive chemotherapy or allogeneic hematopoietic stem cell transplantation.

Riwes MM, Leather H, Neal D, Bennett C, Sugrue M, Cline C, Stokes J, Hiemenz J, Hsu J, Wingard JR.

Bone Marrow Transplant. 2016 Sep;51(9):1228-32. doi: 10.1038/bmt.2016.92. Epub 2016 Apr 18.

PMID:
27088382
41.

Burden, quality of life, and social support in caregivers of patients undergoing radiotherapy for head and neck cancer: A pilot study.

Nightingale CL, Curbow BA, Wingard JR, Pereira DB, Carnaby GD.

Chronic Illn. 2016 Sep;12(3):236-45. doi: 10.1177/1742395316644305. Epub 2016 Apr 10.

42.

Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201.

Burns LJ, Logan BR, Chitphakdithai P, Miller JP, Drexler R, Spellman S, Switzer GE, Wingard JR, Anasetti C, Confer DL; Blood and Marrow Transplant Clinical Trials Network.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1108-1116. doi: 10.1016/j.bbmt.2016.02.018. Epub 2016 Mar 21.

43.

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.

Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, Green JS, Saad A, Antin JH, Savani BN, Lazarus HM, Seftel M, Saber W, Marks D, Aljurf M, Norkin M, Wingard JR, Lindemans CA, Boeckh M, Riches ML, Auletta JJ.

Blood. 2016 May 19;127(20):2427-38. doi: 10.1182/blood-2015-11-679639. Epub 2016 Feb 16.

44.

Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells.

Villa NY, Bais S, Chan WM, Meacham AM, Wise E, Rahman MM, Moreb JS, Rosenau EH, Wingard JR, McFadden G, Cogle CR.

Cytotherapy. 2016 Mar;18(3):465-80. doi: 10.1016/j.jcyt.2015.12.007.

45.

Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis.

Riches ML, Trifilio S, Chen M, Ahn KW, Langston A, Lazarus HM, Marks DI, Martino R, Maziarz RT, Papanicolou GA, Wingard JR, Young JA, Bennett CL.

Bone Marrow Transplant. 2016 Feb;51(2):322. doi: 10.1038/bmt.2015.318. No abstract available.

PMID:
26838373
46.

The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis.

Williams KM, Ahn KW, Chen M, Aljurf MD, Agwu AL, Chen AR, Walsh TJ, Szabolcs P, Boeckh MJ, Auletta JJ, Lindemans CA, Zanis-Neto J, Malvezzi M, Lister J, de Toledo Codina JS, Sackey K, Chakrabarty JL, Ljungman P, Wingard JR, Seftel MD, Seo S, Hale GA, Wirk B, Smith MS, Savani BN, Lazarus HM, Marks DI, Ustun C, Abdel-Azim H, Dvorak CC, Szer J, Storek J, Yong A, Riches MR.

Bone Marrow Transplant. 2016 Apr;51(4):573-80. doi: 10.1038/bmt.2015.316. Epub 2016 Jan 4.

47.

Improved Detection of Invasive Pulmonary Aspergillosis Arising during Leukemia Treatment Using a Panel of Host Response Proteins and Fungal Antigens.

Brasier AR, Zhao Y, Spratt HM, Wiktorowicz JE, Ju H, Wheat LJ, Baden L, Stafford S, Wu Z, Issa N, Caliendo AM, Denning DW, Soman K, Clancy CJ, Nguyen MH, Sugrue MW, Alexander BD, Wingard JR.

PLoS One. 2015 Nov 18;10(11):e0143165. doi: 10.1371/journal.pone.0143165. eCollection 2015.

48.

Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis.

Riches ML, Trifilio S, Chen M, Ahn KW, Langston A, Lazarus HM, Marks DI, Martino R, Maziarz RT, Papanicolou GA, Wingard JR, Young JA, Bennett CL.

Bone Marrow Transplant. 2016 Feb;51(2):277-82. doi: 10.1038/bmt.2015.263. Epub 2015 Nov 2. Erratum in: Bone Marrow Transplant. 2016 Feb;51(2):322.

49.

Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902).

Wood WA, Le-Rademacher J, Syrjala KL, Jim H, Jacobsen PB, Knight JM, Abidi MH, Wingard JR, Majhail NS, Geller NL, Rizzo JD, Fei M, Wu J, Horowitz MM, Lee SJ.

Cancer. 2016 Jan 1;122(1):91-8. doi: 10.1002/cncr.29717. Epub 2015 Oct 6.

50.

Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors.

Young JH, Logan BR, Wu J, Wingard JR, Weisdorf DJ, Mudrick C, Knust K, Horowitz MM, Confer DL, Dubberke ER, Pergam SA, Marty FM, Strasfeld LM, Brown JWM, Langston AA, Schuster MG, Kaul DR, Martin SI, Anasetti C; Blood and Marrow Transplant Clinical Trials Network Trial 0201.

Biol Blood Marrow Transplant. 2016 Feb;22(2):359-370. doi: 10.1016/j.bbmt.2015.09.013. Epub 2015 Sep 25.

Supplemental Content

Loading ...
Support Center